Education
About Us
Working with TipRanks
Follow Us
Lexeo Therapeutics, Inc. (LXEO)
NASDAQ:LXEO
LXEO Stock Chart & Stats
$6.76
-$0.29(-4.02%)
At close: 4:00 PM EST
$6.76
-$0.29(-4.02%)
Day’s Range― - ―
52-Week Range$1.45 - $10.99
Previous CloseN/A
Volume22.32K
Average Volume (3M)686.28K
Market Cap
$493.39M
Enterprise Value$460.86M
Total Cash (Recent Filing)$41.00M
Total Debt (Recent Filing)$8.46M
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Mar 16, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding72,987,330
10 Day Avg. Volume559,453
30 Day Avg. Volume686,278
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-2.56
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-299.06
Enterprise Value/Ebitda-4.49
Forecast
1Y Price Target
$18.00Price Target Upside166.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker EvidenceBiopsy results showing increased PKP2 protein indicate the drug engages its intended target, supporting biological activity and early proof-of-mechanism for the cardiac gene therapy program.
Strategic CollaborationAnalyst's recommendation to buy is supported by a strategic collaboration with Johnson & Johnson that adds development and commercial credibility to the cardiac gene therapy platform.
Valuation FloorExisting value in the company's established program provides a valuation floor that helps limit downside risk if the PKP2 program's results are mixed or safety-limited.
Bears Say
Confounding MedicationsBackground use or changes in anti-arrhythmic medications can create the appearance of efficacy in small studies, complicating assessment of the therapy's true benefit without medication normalization.
Efficacy InconsistencyKey arrhythmia measures have not reliably improved within the same patients, raising concern that reported average improvements may not reflect consistent individual-level benefit.
Safety And Regulatory RiskA new or worsening safety signal, combined with data-driven investor positioning, could significantly weaken the investment thesis, reduce approval probability in models, and increase stock volatility toward the support offered by existing assets.
Lexeo Therapeutics, Inc. News
LXEO FAQ
What was Lexeo Therapeutics, Inc.’s price range in the past 12 months?
Lexeo Therapeutics, Inc. lowest stock price was $1.45 and its highest was $10.99 in the past 12 months.
What is Lexeo Therapeutics, Inc.’s market cap?
Lexeo Therapeutics, Inc.’s market cap is $493.39M.
When is Lexeo Therapeutics, Inc.’s upcoming earnings report date?
Lexeo Therapeutics, Inc.’s upcoming earnings report date is Mar 16, 2026 which is in 9 days.
How were Lexeo Therapeutics, Inc.’s earnings last quarter?
Lexeo Therapeutics, Inc. released its earnings results on Nov 05, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.52 by $0.19.
Is Lexeo Therapeutics, Inc. overvalued?
According to Wall Street analysts Lexeo Therapeutics, Inc.’s price is currently Undervalued.
Does Lexeo Therapeutics, Inc. pay dividends?
Lexeo Therapeutics, Inc. does not currently pay dividends.
What is Lexeo Therapeutics, Inc.’s EPS estimate?
Lexeo Therapeutics, Inc.’s EPS estimate is -0.32.
How many shares outstanding does Lexeo Therapeutics, Inc. have?
Lexeo Therapeutics, Inc. has 72,987,330 shares outstanding.
What happened to Lexeo Therapeutics, Inc.’s price movement after its last earnings report?
Lexeo Therapeutics, Inc. reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.52. Following the earnings report the stock price went down -1.796%.
Which hedge fund is a major shareholder of Lexeo Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LXEO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lexeo Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.00 (166.27% Upside)
$18.00 (166.27% Upside)
Blogger Sentiment
Bullish
LXEO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $84.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
149.44%
12-Months-Change
Fundamentals
Return on Equity
-80.69%
Trailing 12-Months
Asset Growth
-17.27%
Trailing 12-Months
Company Description
Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
LXEO Stock 12 Month Forecast
Average Price Target
$18.00
▲(166.27% Upside)
Technical Analysis
Tvardi Therapeutics
―
Larimar Therapeutics
―
Capricor Therapeutics
―
Benitec Biopharma
―
Diamedica Therapeutics
―
Ownership Overview
1.18% Insiders
5.60% Mutual Funds
14.89% Other Institutional Investors
65.29% Public Companies and
Individual Investors